Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

Completed · Phase 1

Conditions studied: Diabetes, Diabetes Mellitus, Type 2, Delivery Systems

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.

Key facts

Study ID

NCT00127296

Run by

Novo Nordisk A/S

People needed

60

Starts

2005-07-01

Expected to finish

2005-09-01

Last updated by the study team

2017-01-06

Who can join

Age: 40 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes
• Insulin naive
• No previous experience administering injections

You may not qualify if…

• Any condition that, in the Investigator and/or Sponsor's opinion, could interfere with the results of this trial

Where it is running

• Novo Nordisk Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.